Journal
ALZHEIMERS & DEMENTIA
Volume 17, Issue 9, Pages 1528-1553Publisher
WILEY
DOI: 10.1002/alz.12311
Keywords
Alzheimer' s disease; biomarkers; clinical trials; dementia; electroencephalography (EEG); eyes‐ closed resting state condition; The Alzheimer' s Association International Society to Advance Alzheimer' s Research and Treatment (ISTAART)
Categories
Ask authors/readers for more resources
The Electrophysiology Professional Interest Area and Global Brain Consortium endorsed recommendations on EEG measures for Alzheimer's disease clinical trials, emphasizing the need for standardized measurement methods and international collaboration.
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and interrelatedness at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and interrelatedness rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available